Clinics in Dermatology
Volume 26, Issue 3 , Pages 288-295 , May 2008

Cutaneous manifestations of pituitary gland diseases

References 

  1. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf). 1993;38:571–578
  2. Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab. 2000;85:3779–3785
  3. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 2005;62:210–216
  4. Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf). 2002;57:713–717
  5. Thorner MO, Vance ML, Laws ER, et al. The anterior pituitary. In:  Wilson JD,  Foster DW,  Kronenberg HM, et al. editor. Williams textbook of endocrinology. 9th ed.. Philadelphia: WB Saunders; 1998;p. 295–307
  6. Van Wyk JJ, Underwood LE. Relation between growth hormone and somatomedin. Annu Rev Med. 1975;26:427–441
  7. Matsuoka LY, Wortsman J, Kupchella CE, et al. Histochemical characterization of the cutaneous involvement of acromegaly. Arch Intern Med. 1982;142:1820–1823
  8. Mekamed S. Clinical manifestations of acromegaly. UpToDate. 1998;6:1–5
  9. MacFarlane IA, Knass D, Beardwell CG, et al. Hyperhidrosis in acromegaly: effectiveness of topical aluminium chloride hexahydrate solution. Br J Med. 1979;2:901–902
  10. Burton JL, Libman LJ, Cunliffe WJ, et al. Sebum excretion in acromegaly. Br J Med. 1972;1:406–408
  11. Chalmers RJ, Ead RD, Beck MH, et al. Acne vulgaris and hidradenitis suppurativa as presenting features of acromegaly. BMJ (Clin Res Ed). 1983;287:1346–1347
  12. Brown J, Winkelmann RK, Randall RV. Acanthosis nigricans and pituitary tumors, report of eight cases. JAMA. 1966;198:619–623
  13. Levin SR, Hofeldt FD, Becker N, et al. Hypersomatotropism and acanthosis nigricans in two brothers. Arch Intern Med. 1974;134:365–367
  14. Trouillas J, Sassolas G, Guigard MP, et al. Relationships between pathological diagnosis and clinical parameters in acromegaly. Metab Clin Exp. 1996;45:53–56
  15. Weber G, Neidhardt M, Schmidt A. Korrelation von Wachstumshormon und klinischem Bild der Psoriasis. Arch Dermatol Res. 1981;270:129–140
  16. Weber G, Pliess G, Heitz U. Growth hormone producing hyperplasia of pituitary gland in psoriasis. Arch Dermatol Res. 1985;277:345
  17. Weber G, Heitz U, Pliess G. Hyperplasia of growth hormone producing cells in the hypophysis in psoriasis, study of 10 patients. Hautarzt. 1986;37:458–462
  18. Mackie RM, Beastall GM, Thomson JA. Growth hormone levels in psoriasis. Arch Dermatol Res. 1984;275:207–208
  19. Vernier A, De Simone C, Forri L, et al. Treatment of severe psoriasis with somatostatin: four years of experience. Arch Dermatol Res. 1988;280(Suppl):51–54
  20. Todd DJ, Eedy DJ, McMillan JC. Acromegaly and psoriasis. Clin Exp Dermatol. 1991;16:222–223
  21. Guilhou JJ. Growth hormone, somatostatin and psoriasis. Dermatologica. 1990;181:81–82
  22. Mekamed S. Diagnosis of acromegaly. UpToDate. 1997;6:1–4
  23. Ezzat S. Acromegaly. Endocrinol Metab Clin North Am. 1997;26:703–723
  24. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526–529
  25. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of SR-lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab. 1999;84:527–532
  26. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002;56:65–71
  27. Freda PU. How effective are current therapies for acromegaly?. Growth Horm IGF Res. 2003;13:S144–S151
  28. Meema HE, Sheppard RH, Rapoport A. Roentgenographic visualization and measurement of skin thickness and its diagnostic application in acromegaly. Radiology. 1964;82:411–417
  29. Fields ML, Greenberg BH, Burkett LL. Roentgenographic measurement of skin and heel-pad thickness in the diagnosis of acromegaly. Am J Med Sci. 1967;254:528–533
  30. Gooding GA, Stress RM, Graf PM, et al. Heel pad thickness: determination by high-resolution ultrasonography. J Ultrasound Med. 1985;4:173–174
  31. Lang PG. Adrenal disorders. In:  Callen JP editors. Cutaneous aspects of internal disease. London: Year Book Medical Publishers; 1981;p. 451–462
  32. Deacon SP. Pituitary-dependent Cushing's disease. BMJ. 1977;1:1409
  33. Yanovski JA, Cutler GB. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994;23:487–509
  34. Fisher LB, Maibach HI. The effect of corticosteroids on human epidermal mitotic activity. Arch Dermatol. 1971;103:39–44
  35. Rokowski K, Sheehy J, Cutroneo KR. Glucocorticoid-mediated selective reduction of functioning collagen messenger ribonucleic acid. Arch Biochem Biophys. 1981;210:74–81
  36. Findling JW, Raff H. Diagnosis and differential diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am. 2001;30:729–747
  37. Matsuoka LY, Wortsman J, Gavin JR, et al. Spectrum of endocrine abnormalities associated with acanthosis nigricans. Am J Med. 1987;83:719–725
  38. Winkelmann RK, Scheen SR, Underdahl LO. Acanthosis nigricans and endocrine disease. JAMA. 1960;174:1145–1152
  39. Freinkel RK. Cutaneous manifestations of endocrine diseases. In:  Fitzpatrick TB,  Eisen AZ,  Wolf K, et al. editor. Dermatology in general medicine. 4th ed.. New York: McGraw-Hill; 1993;p. 2113–2131
  40. Findling JW, Raff H. Newer diagnostic techniques and problems in Cushing's disease. Endocrinol Metab Clin North Am. 1999;28:191–210
  41. Meier CA, Biller BM. Clinical and biochemical evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am. 1997;26:741–762
  42. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109:487–493
  43. Doyle D, O'Donovan DK. More on cyproheptadine in Cushing's disease (letter). N Engl J Med. 1977;296:576
  44. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003;4:315–331
  45. Jara LJ, Lavalle C, Fraga A, et al. Prolactin, immunoregulation, and autoimmune diseases. Semin Arthritis Rheum. 1991;20:273–284
  46. Russell DH, Kibler R, Matrisian L, et al. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol. 1985;134:3027–3031
  47. Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol. 1991;26:118–123
  48. Girolomoni G, Phillips JT, Bergstresser PR. Prolactin stimulates proliferation of cultured human keratinocytes. J Invest Dermatol. 1993;101:275–279
  49. Giasuddin ASM, El-Sherif AI, El-Ojali SI. Prolactin: does it have a role in the pathogenesis of psoriasis. Dermatology. 1998;197:119–122
  50. Carr BR. Disorders of the ovaries and female reproductive tract. In:  Wilson JD,  Foster DW,  Kronenberg HM, et al. editor. Williams textbook of endocrinology. 9th ed.. Philadelphia: WB Saunders; 1998;p. 795–799
  51. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1998;27:877–902
  52. Regana MS, Millet PU. Psoriasis in association with prolactinoma: three cases. Br J Dermatol. 2000;143:864–867
  53. Molitch ME, Thorner MO, Wilson CB. Management of prolactinomas: overview and introduction. J Clin Endocrinol Metab. 1997;82:996–1000
  54. Zikel OM, Atkinson JLD, Hurley DL. Prolactinoma manifesting with symptomatic hydrocephalus. Mayo Clin Proc. 1999;74:475–477
  55. Saeed S, Farooqi OA, Panayiotou B, et al. Reversible confusional state in an elderly man. Postgrad Med J. 1999;75:365–366
  56. Iglesias P, Macho LP, Diez JJ. Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy. Age Ageing. 2004;33:410–412
  57. Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus. 2004;16:E2
  58. Vance ML. Hypopituitarism. N Engl J Med. 1994;330:1651–1662
  59. Daughaday WH. The anterior pituitary. In:  Wilson JD,  Foster DW editor. Textbook of endocrinology. 7th ed.. Philadelphia: WB Saunders; 1985;p. 568–613
  60. Freinkel RK, Freinkel N. Dermatologic manifestations of endocrine diseases. In:  Fitzpatrick TB,  Eisen AZ,  Wolf K, et al. editor. Dermatology in general medicine. 3rd ed.. New York: McGraw-Hill; 1986;p. 2063–2081

PII: S0738-081X(07)00239-8

doi: 10.1016/j.clindermatol.2007.10.016

Clinics in Dermatology
Volume 26, Issue 3 , Pages 288-295 , May 2008

Article Tools